Galderma Group stock
GALD.SWSIXGalderma Group AG, HealthcareISIN CH1335392721
64Score 64 out of 100, Neutral
Price and trend
81 / 100
Price history
+27% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is at its 52-week high. Largest decline in 3 years: 39% (February 2025 to April 2025).
Chart figures for advanced users
- SMA 50$207.08
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$198.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$171.23
- The lowest closing price of the last twelve months.
- Resistance$235.16
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Galderma Group AG belongs to the Drug Manufacturers (Specialty & Generic) industry (Switzerland) and, with a market value of $54.63B, is number 3 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.24B (up 7.2% year on year) and earnings of $642.16M (up 152.5%).
- MEQIRI Score 64 out of 100 (Neutral): rank 228 of 714 in Healthcare, median 53.
Show more
- The P/E is 64.2 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 89.4).
- Our model puts fair value at $179.56, with the price 31% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 30.5% a year through 2028 (estimates from 13 analysts).Growth 75
- Earnings turn into cashFree cash flow 121% of earnings over the last 12 months.Fundamentals 56
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $128.26 and expensive above $299.27 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $288.52 (cash-flow model) and $70.59 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $152.87, at 7.8% it would be $219.84.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Jun 2026, revenue rose 16.1% on the same quarter a year earlier. Revenue has grown solidly since 2021, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating 16%, net 12%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 11 Mar 2027in 119 days
- Last reported
- 23 Jul 2026EPS reported 1.91 (expected 1.83)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 4.96−0.4%
- Revenue
- $6.58B−0.8%
- Earnings per share
- 6.75−0.9%
- Revenue
- $7.89B+0.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Galderma Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 64
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Merck KGaAMRK.DE $73.34B68
- Takeda PharmaceuticalTAK $68.06B57
- Teva Pharmaceutical IndustriesTEVA $50.45B54
- Sun Pharmaceutical IndustriesSUNPHARMA.NS $48.71B72
- Jiangsu Hengrui Medicine600276.SS $46.11B70
- Sandoz GroupSDZ.SW $44.42B66
- Jiangsu Hengrui Pharmaceuticals1276.HK $42.51B67
- HaleonHLN $40.35B61
ETFs that hold Galderma Group
Held by 106 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers SLI UCITS ETF 1DDXS0 | 3.59% | 0.25% | €581.42M |
| Amundi DJ Switzerland Titans 30 UCITS ETF DistC030 | 2.56% | 0.25% | €237.76M |
| Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc540H | 2.37% | 0.30% | €182.66M |
Show 5 more
| Xtrackers Switzerland UCITS ETF 1DXSMI | 2.37% | 0.30% | €2.88B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 2.21% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 2.21% | 0.18% | €954.9M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 2.17% | 0.46% | €729.65M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 2.17% | 0.18% | €653.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 May 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.